Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Reproductive system and breast disorders – page 3

  • 960 clinical trials
  • 390 recruiting
  • 346 conditions
  • 28 countries

Conditions in this area

346 conditions with trials, the busiest first

Breast cancer170Prostate cancer102Ovarian cancer90Breast cancer metastatic84Triple negative breast cancer69Hormone receptor positive HER2 negative breast cancer62Hormone-refractory prostate cancer56Endometrial cancer53Prostate cancer metastatic48HER2 positive breast cancer42Hormone receptor positive breast cancer42Cervix carcinoma35Fallopian tube cancer30Breast cancer female27Non-small cell lung cancer25Infertility female22Hormone-dependent prostate cancer19Infertility18Ovarian cancer recurrent18Ovarian epithelial cancer18Colorectal cancer12Gastric cancer12Head and neck cancer12Malignant peritoneal neoplasm12+322

Clinical trials in Reproductive system and breast disorders

960 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

960 clinical trials

Lichen sclerosus

Recruiting

A study to evaluate the effectiveness of methotrexate in preventing the recurrence of dermatological vulvar intraepithelial neoplasia in women with lichen sclerosus.

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Methotrexate
  • Sponsor:Amsterdam UMC Stichting

Endometrial cancer+12

Recruiting

A study of belzutifan and lenvatinib for patients with von Hippel-Lindau disease-associated tumors or other specific solid tumors.

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Belzutifan
  • Sponsor:Merck Sharp & Dohme LLC

Gastric cancer+4

Recruiting

A study to evaluate the use of [68Ga]BED003 for imaging colorectal, gastric, pancreatic, breast, and ovarian cancers.

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years

Ovarian cancer

Recruiting

A study of sacituzumab tirumotecan and bevacizumab in patients with newly diagnosed advanced ovarian cancer following first-line platinum-based chemotherapy

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Merck Sharp & Dohme LLC

Neoplasm malignant+1

Recruiting

A Phase I/II Study of GVV858 Alone or in Drug Combination for Patients with Advanced Hormone Receptor‑Positive, HER2‑Negative Breast Cancer

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Fulvestrant
  • Sponsor:Novartis Pharma AG

Breast cancer+1

Recruiting

Maintenance Therapy Study of Inavolisib with Pertuzumab and Trastuzumab in Patients with HER2‑Positive, PIK3CA‑Mutated Locally Advanced or Metastatic Breast Cancer

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Anastrozole
  • Sponsor:F. Hoffmann-La Roche AG

Infertility male

Recruiting

A study to evaluate the use of leflutrozole to improve semen quality in men with non-obstructive azoospermia

InvestigationalNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years · Healthy volunteers
  • Sponsor:Region Hovedstaden

Adenomyosis

Recruiting

A study to evaluate the effect of valproic acid in women of reproductive age with adenomyosis

Registered drug
Countries:BulgariaBulgaria
  • Participants:18–64 years
  • Substances:Ibuprofen
  • Sponsor:CCDRD Cooperative Clinical Drug Research and Development AG

Endometrial adenocarcinoma

Recruiting

A study of tirzepatide and levonorgestrel in women with endometrial cancer

Registered drugNo placebo
Countries:IrelandIreland
  • Participants:18–64 years · 65+ years
  • Substances:Levonorgestrel
  • Sponsor:University College Dublin

Triple negative breast cancer

Recruiting

Study of pembrolizumab, capecitabine, or olaparib in patients with early-stage triple negative breast cancer and remaining disease after initial treatment

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting

Ovarian epithelial cancer

Recruiting

Comparing AZD5335 with mirvetuximab soravtansine or a drug combination in patients with platinum-resistant ovarian cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:AZD5335
  • Sponsor:AstraZeneca AB

Endometrial cancer+2

Recruiting

A study comparing Rinatabart Sesutecan to other treatments in patients with endometrial cancer who have previously received platinum-based chemotherapy and PD-L1 therapy

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Paclitaxel
  • Sponsor:Genmab A/S

Substances studied in this area

The therapies tested most often in Reproductive system and breast disorders trials.

Paclitaxel118 clinical trialsCarboplatin86 clinical trialsPembrolizumab76 clinical trialsLetrozole74 clinical trialsFulvestrant59 clinical trialsDocetaxel49 clinical trialsEnzalutamide49 clinical trialsExemestane47 clinical trialsAnastrozole45 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.